279 related articles for article (PubMed ID: 29263880)
1. Cellular and molecular synergy in AS01-adjuvanted vaccines results in an early IFNγ response promoting vaccine immunogenicity.
Coccia M; Collignon C; Hervé C; Chalon A; Welsby I; Detienne S; van Helden MJ; Dutta S; Genito CJ; Waters NC; Deun KV; Smilde AK; Berg RAVD; Franco D; Bourguignon P; Morel S; Garçon N; Lambrecht BN; Goriely S; Most RV; Didierlaurent AM
NPJ Vaccines; 2017; 2():25. PubMed ID: 29263880
[TBL] [Abstract][Full Text] [Related]
2. Enhancement of adaptive immunity by the human vaccine adjuvant AS01 depends on activated dendritic cells.
Didierlaurent AM; Collignon C; Bourguignon P; Wouters S; Fierens K; Fochesato M; Dendouga N; Langlet C; Malissen B; Lambrecht BN; Garçon N; Van Mechelen M; Morel S
J Immunol; 2014 Aug; 193(4):1920-30. PubMed ID: 25024381
[TBL] [Abstract][Full Text] [Related]
3. Updated insights into the mechanism of action and clinical profile of the immunoadjuvant QS-21: A review.
Lacaille-Dubois MA
Phytomedicine; 2019 Jul; 60():152905. PubMed ID: 31182297
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant system AS01: helping to overcome the challenges of modern vaccines.
Didierlaurent AM; Laupèze B; Di Pasquale A; Hergli N; Collignon C; Garçon N
Expert Rev Vaccines; 2017 Jan; 16(1):55-63. PubMed ID: 27448771
[TBL] [Abstract][Full Text] [Related]
5. CCR2- and Flt3-Dependent Inflammatory Conventional Type 2 Dendritic Cells Are Necessary for the Induction of Adaptive Immunity by the Human Vaccine Adjuvant System AS01.
Bosteels C; Fierens K; De Prijck S; Van Moorleghem J; Vanheerswynghels M; De Wolf C; Chalon A; Collignon C; Hammad H; Didierlaurent AM; Lambrecht BN
Front Immunol; 2020; 11():606805. PubMed ID: 33519816
[TBL] [Abstract][Full Text] [Related]
6. Toll-like receptor 4 signaling in hematopoietic-lineage cells contributes to the enhanced activity of the human vaccine adjuvant AS01.
Van Maele L; Fougeron D; Cayet D; Chalon A; Piccioli D; Collignon C; Sirard JC; Didierlaurent AM
Eur J Immunol; 2019 Dec; 49(12):2134-2145. PubMed ID: 31489613
[TBL] [Abstract][Full Text] [Related]
7. Recent clinical experience with vaccines using MPL- and QS-21-containing adjuvant systems.
Garçon N; Van Mechelen M
Expert Rev Vaccines; 2011 Apr; 10(4):471-86. PubMed ID: 21506645
[TBL] [Abstract][Full Text] [Related]
8. Central Role of CD169
Detienne S; Welsby I; Collignon C; Wouters S; Coccia M; Delhaye S; Van Maele L; Thomas S; Swertvaegher M; Detavernier A; Elouahabi A; Goriely S; Didierlaurent AM
Sci Rep; 2016 Dec; 6():39475. PubMed ID: 27996000
[TBL] [Abstract][Full Text] [Related]
9. Monophosphoryl lipid A (MPL) as an adjuvant for anti-cancer vaccines: clinical results.
Cluff CW
Adv Exp Med Biol; 2010; 667():111-23. PubMed ID: 20665204
[TBL] [Abstract][Full Text] [Related]
10. The Lymphatic Immune Response Induced by the Adjuvant AS01: A Comparison of Intramuscular and Subcutaneous Immunization Routes.
Neeland MR; Shi W; Collignon C; Taubenheim N; Meeusen EN; Didierlaurent AM; de Veer MJ
J Immunol; 2016 Oct; 197(7):2704-14. PubMed ID: 27549170
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the immune response to RTS,S/AS01 and RTS,S/AS02 adjuvanted vaccines: randomized, double-blind study in malaria-naïve adults.
Leroux-Roels G; Leroux-Roels I; Clement F; Ofori-Anyinam O; Lievens M; Jongert E; Moris P; Ballou WR; Cohen J
Hum Vaccin Immunother; 2014; 10(8):2211-9. PubMed ID: 25424924
[TBL] [Abstract][Full Text] [Related]
12. Cell-mediated immune responses to a varicella-zoster virus glycoprotein E vaccine using both a TLR agonist and QS21 in mice.
Dendouga N; Fochesato M; Lockman L; Mossman S; Giannini SL
Vaccine; 2012 Apr; 30(20):3126-35. PubMed ID: 22326899
[TBL] [Abstract][Full Text] [Related]
13. Improved CD4⁺ T cell responses to Mycobacterium tuberculosis in PPD-negative adults by M72/AS01 as compared to the M72/AS02 and Mtb72F/AS02 tuberculosis candidate vaccine formulations: a randomized trial.
Leroux-Roels I; Forgus S; De Boever F; Clement F; Demoitié MA; Mettens P; Moris P; Ledent E; Leroux-Roels G; Ofori-Anyinam O;
Vaccine; 2013 Apr; 31(17):2196-206. PubMed ID: 22643213
[TBL] [Abstract][Full Text] [Related]
14. Similarities and differences of chemical compositions and physical and functional properties of adjuvant system 01 and army liposome formulation with QS21.
Alving CR; Rao M; Matyas GR
Front Immunol; 2023; 14():1102524. PubMed ID: 36761767
[TBL] [Abstract][Full Text] [Related]
15. Immune response to the hepatitis B antigen in the RTS,S/AS01 malaria vaccine, and co-administration with pneumococcal conjugate and rotavirus vaccines in African children: A randomized controlled trial.
Valéa I; Adjei S; Usuf E; Traore O; Ansong D; Tinto H; Owusu Boateng H; Leach A; Mwinessobaonfou Some A; Buabeng P; Vekemans J; Nana LA; Kotey A; Vandoolaeghe P; Ouedraogo F; Sambian D; Lievens M; Tahita MC; Rettig T; Jongert E; Lompo P; Idriss A; Borys D; Ouedraogo S; Prempeh F; Habib MA; Schuerman L; Sorgho H; Agbenyega T
Hum Vaccin Immunother; 2018 Jun; 14(6):1489-1500. PubMed ID: 29630438
[TBL] [Abstract][Full Text] [Related]
16. Prophylactic Herpes Simplex Virus 2 (HSV-2) Vaccines Adjuvanted with Stable Emulsion and Toll-Like Receptor 9 Agonist Induce a Robust HSV-2-Specific Cell-Mediated Immune Response, Protect against Symptomatic Disease, and Reduce the Latent Viral Reservoir.
Hensel MT; Marshall JD; Dorwart MR; Heeke DS; Rao E; Tummala P; Yu L; Cohen GH; Eisenberg RJ; Sloan DD
J Virol; 2017 May; 91(9):. PubMed ID: 28228587
[TBL] [Abstract][Full Text] [Related]
17. Erratum: Author Correction: Cellular and molecular synergy in AS01-adjuvanted vaccines results in an early IFNγ response promoting vaccine immunogenicity.
Coccia M; Collignon C; Hervé C; Chalon A; Welsby I; Detienne S; van Helden MJ; Dutta S; Genito CJ; Waters NC; Van Deun K; Smilde AK; van den Berg RA; Franco D; Bourguignon P; Morel S; Garçon N; Lambrecht BN; Goriely S; van der Most R; Didierlaurent AM
NPJ Vaccines; 2018; 3():13. PubMed ID: 29582861
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant-Dependent Enhancement of HIV Env-Specific Antibody Responses in Infant Rhesus Macaques.
Phillips B; Van Rompay KKA; Rodriguez-Nieves J; Lorin C; Koutsoukos M; Tomai M; Fox CB; Eudailey J; Dennis M; Alam SM; Hudgens M; Fouda G; Pollara J; Moody A; Shen X; Ferrari G; Permar S; De Paris K
J Virol; 2018 Oct; 92(20):. PubMed ID: 30089691
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant-Associated Peripheral Blood mRNA Profiles and Kinetics Induced by the Adjuvanted Recombinant Protein Candidate Tuberculosis Vaccine M72/AS01 in Bacillus Calmette-Guérin-Vaccinated Adults.
van den Berg RA; De Mot L; Leroux-Roels G; Bechtold V; Clement F; Coccia M; Jongert E; Evans TG; Gillard P; van der Most RG
Front Immunol; 2018; 9():564. PubMed ID: 29632533
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of the RTS,S/AS01E candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trial.
Asante KP; Abdulla S; Agnandji S; Lyimo J; Vekemans J; Soulanoudjingar S; Owusu R; Shomari M; Leach A; Jongert E; Salim N; Fernandes JF; Dosoo D; Chikawe M; Issifou S; Osei-Kwakye K; Lievens M; Paricek M; Möller T; Apanga S; Mwangoka G; Dubois MC; Madi T; Kwara E; Minja R; Hounkpatin AB; Boahen O; Kayan K; Adjei G; Chandramohan D; Carter T; Vansadia P; Sillman M; Savarese B; Loucq C; Lapierre D; Greenwood B; Cohen J; Kremsner P; Owusu-Agyei S; Tanner M; Lell B
Lancet Infect Dis; 2011 Oct; 11(10):741-9. PubMed ID: 21782519
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
